NSEI:DCAL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide.


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Dishman Carbogen Amcis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DCAL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

20.2%

DCAL

0.9%

IN Life Sciences

2.0%

IN Market


1 Year Return

-29.7%

DCAL

31.4%

IN Life Sciences

-5.4%

IN Market

Return vs Industry: DCAL underperformed the Indian Life Sciences industry which returned 31.4% over the past year.

Return vs Market: DCAL underperformed the Indian Market which returned -5.4% over the past year.


Shareholder returns

DCALIndustryMarket
7 Day20.2%0.9%2.0%
30 Day24.6%-4.0%7.0%
90 Day124.7%5.0%18.6%
1 Year-29.6%-29.7%33.2%31.4%-3.5%-5.4%
3 Yearn/a160.0%153.0%1.0%-3.8%
5 Yearn/a138.1%124.7%25.6%15.9%

Price Volatility Vs. Market

How volatile is Dishman Carbogen Amcis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dishman Carbogen Amcis undervalued compared to its fair value and its price relative to the market?

13.63x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DCAL (₹152.65) is trading above our estimate of fair value (₹66.93)

Significantly Below Fair Value: DCAL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DCAL is good value based on its PE Ratio (13.6x) compared to the IN Life Sciences industry average (35.1x).

PE vs Market: DCAL is poor value based on its PE Ratio (13.6x) compared to the Indian market (12.6x).


Price to Earnings Growth Ratio

PEG Ratio: DCAL is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: DCAL is good value based on its PB Ratio (0.4x) compared to the IN Life Sciences industry average (1.1x).


Next Steps

Future Growth

How is Dishman Carbogen Amcis forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

14.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DCAL's forecast earnings growth (14.9% per year) is above the savings rate (7.2%).

Earnings vs Market: DCAL's earnings (14.9% per year) are forecast to grow slower than the Indian market (18.9% per year).

High Growth Earnings: DCAL's earnings are forecast to grow, but not significantly.

Revenue vs Market: DCAL's revenue (7.7% per year) is forecast to grow faster than the Indian market (7.3% per year).

High Growth Revenue: DCAL's revenue (7.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DCAL's Return on Equity is forecast to be low in 3 years time (3.5%).


Next Steps

Past Performance

How has Dishman Carbogen Amcis performed over the past 5 years?

28.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DCAL has high quality earnings.

Growing Profit Margin: DCAL's current net profit margins (8.8%) are lower than last year (10.2%).


Past Earnings Growth Analysis

Earnings Trend: DCAL has become profitable over the past 5 years, growing earnings by 28.6% per year.

Accelerating Growth: DCAL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DCAL had negative earnings growth (-14.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-6.2%).


Return on Equity

High ROE: DCAL's Return on Equity (3.1%) is considered low.


Next Steps

Financial Health

How is Dishman Carbogen Amcis's financial position?


Financial Position Analysis

Short Term Liabilities: DCAL's short term assets (₹18.0B) exceed its short term liabilities (₹15.7B).

Long Term Liabilities: DCAL's short term assets (₹18.0B) exceed its long term liabilities (₹9.2B).


Debt to Equity History and Analysis

Debt Level: DCAL's debt to equity ratio (16.2%) is considered satisfactory.

Reducing Debt: DCAL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: DCAL's debt is well covered by operating cash flow (63%).

Interest Coverage: DCAL's interest payments on its debt are well covered by EBIT (3.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Dishman Carbogen Amcis's current dividend yield, its reliability and sustainability?

0.13%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DCAL's dividend (0.13%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.69%).

High Dividend: DCAL's dividend (0.13%) is low compared to the top 25% of dividend payers in the Indian market (2.73%).


Stability and Growth of Payments

Stable Dividend: DCAL is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: DCAL is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DCAL is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DCAL's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

Arpit Vyas (34yo)

no data

Tenure

₹12,000,000

Compensation

Mr. Arpit Janmejay Vyas has been Group Managing Director of Dishman Carbogen Amcis Limited since November 28, 2018 and as its Director since April 7, 2012. He is the Global CFO at Carbogen Amcis AG. He ser ...


CEO Compensation Analysis

Compensation vs Market: Arpit's total compensation ($USD159.74K) is below average for companies of similar size in the Indian market ($USD358.82K).

Compensation vs Earnings: Arpit's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Janmejay Vyas
Chairman of the Boardno data₹15.82m0.0019% 441.5k
Arpit Vyas
Group MD & Directorno data₹12.00m0.00064% 148.0k
Mark Griffiths
Director of Global Marketing & Strategy and Director3.33yrsno datano data
Deohooti Vyas
Whole Time Director3.33yrs₹12.00m0.00064% 148.0k
Ashok Gandhi
Independent Director3.33yrs₹1.48mno data
Sanjay Majmudar
Independent Director3.33yrs₹1.90m0.016% 3.6m
Subir Das
Independent Director3.33yrs₹1.33mno data
Rajendra Shah
Independent Director3.33yrs₹920.00kno data
Maitri Mehta
Independent Director1.25yrsno datano data

3.3yrs

Average Tenure

67yo

Average Age

Experienced Board: DCAL's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Dishman Carbogen Amcis Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dishman Carbogen Amcis Limited
  • Ticker: DCAL
  • Exchange: NSEI
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹23.118b
  • Shares outstanding: 156.78m
  • Website: https://www.dishmangroup.com

Location

  • Dishman Carbogen Amcis Limited
  • Dishman Corporate House
  • Opposite Jayantilal Park BRTS Bus Stop
  • Ahmedabad
  • Gujarat
  • 380058
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
540701BSE (Mumbai Stock Exchange)YesEquity SharesININRSep 2017
DCALNSEI (National Stock Exchange of India)YesEquity SharesININRSep 2017

Biography

Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. It also manufactures and supplies marketable molecules, such as bulk drugs, intermediates, quaternary ammonium compounds, specialty chemicals, vitamins and chemicals, and disinfectants. The company was incorporated in 2007 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/10 13:00
End of Day Share Price2020/07/10 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.